

Atrial fibrillation follow-up investigation of rhythm management design. The Planning and Steering Committees of the Atrial Fibrillation Investigators

American Journal of Cardiology
79, 1198-202

Citation Report

#	ARTICLE	IF	CITATIONS
1	lbutilide. Drugs, 1997, 54, 312-330.	10.9	41
2	Definitions and endpoints for device clinical trials in atrial fibrillation--a pressing need. , 1997, 1, 173-174.		5
3	Be still my beating heart--the Ablate and Pace Study. , 1998, 2, 137-138.		3
4	Unexpected instant death following successful coronary artery bypass graft surgery (and other) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Cardiology, 1998, 21, 711-718.	1.8	9
5	Contemporary Utilization of Digoxin in Patients with Atrial Fibrillation. Annals of Pharmacotherapy, 1999, 33, 289-293.	1.9	11
6	Radiofrequency Catheter Ablation Techniques for the Treatment of Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 100-102.	1.0	1
7	Catheter-ablative techniques for the treatment of atrial fibrillation. Current Cardiology Reports, 1999, 1, 142-148.	2.9	1
8	Guidelines for Stroke Prevention in Patients with Atrial Fibrillation. Drugs, 1999, 58, 997-1009.	10.9	18
9	Dofetilide. Drugs, 1999, 58, 1043-1059.	10.9	35
10	An Overview of Contemporary Approaches to Antiarrhythmic Therapy. Japanese Circulation Journal, 1999, 63, 655-658.	1.0	1
11	ä,æ•è,,^æ²»ç™,ã@æœ€ã%ç.šã€€ã€€ã¿fæ^;ç°ã•ã@è"ç™,ã@é€²æ©. The Journal of the Japanese Society of Internal Medicine, 2000, 89		
12	The AFFIRM trial: main trial and substudies-what can We expect?. , 2000, 4, 171-176.		28
13	Overview of Atrial Fibrillation Trials. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 149-155.	1.0	1
14	Cost Effectiveness of Therapies for Atrial Fibrillation. Pharmacoeconomics, 2000, 18, 317-333.	3.3	8
15	Cost-Effectiveness of Antiarrhythmic Drugs for Prevention of Thromboembolism in Patients With Paroxysmal Atrial Fibrillation.. Japanese Circulation Journal, 2001, 65, 765-768.	1.0	6
16	The Utilisation of a Day-Surgery Unit for Direct-Current (DC) Cardioversion of Atrial Fibrillation. Scottish Medical Journal, 2001, 46, 106-107.	1.3	0
17	Atrial fibrillation. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 261-276.	0.9	4
18	factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clinical Cardiology, 2001, 24, 238-244.	1.8	122

#	ARTICLE	IF	CITATIONS
19	Special Considerations for the Elderly Patient with Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 243-253.	1.0	0
20	Long-term Management of Atrial Fibrillation: State of the Art. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 205-208.	1.0	0
21	Atrial Fibrillation: Is Rate Stabilization a Valid Clinical Strategy?. Annals of Noninvasive Electrocardiology, 2001, 6, 81-83.	1.1	0
22	The Year in Review: Cardiology. Journal of Pharmacy Practice, 2001, 14, 18-40.	1.0	0
23	Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. British Heart Journal, 2002, 87, 535-543.	2.1	117
24	Atrial Fibrillation in the Elderly. Drugs and Aging, 2002, 19, 819-846.	2.7	58
25	Arrhythmias in patients with heart failure. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 467-485.	0.9	20
26	Maintaining stability of sinus rhythm in atrial fibrillation: Antiarrhythmic drugs versus ablation. Current Cardiology Reports, 2002, 4, 418-425.	2.9	2
27	Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Heart Failure Reviews, 2002, 7, 285-300.	3.9	21
28	Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Failure Reviews, 2002, 7, 267-283.	3.9	13
29	Rate Control in Atrial Fibrillation. Drugs, 2003, 63, 1489-1509.	10.9	39
30	Pharmacotherapy of Atrial Fibrillation. Asian Cardiovascular and Thoracic Annals, 2003, 11, 364-374.	0.5	3
31	Recent Advances in the Treatment of Arrhythmias. Circulation Journal, 2003, 67, 651-655.	1.6	8
32	Investigation of the Optimal Treatment Strategy for Atrial Fibrillation in Japan-The J-RHYTHM (Japanese) Tj ETQq1 1 0,784314 rgBT /Over	1.6	56
33	Managing atrial fibrillation â€” redrawing a line in the sand. Medical Journal of Australia, 2003, 178, 480-481.	1.7	4
34	Rate Versus Rhythm Control in Atrial Fibrillation. Annals of Pharmacotherapy, 2004, 38, 839-844.	1.9	1
35	Randomized Trials of Rate vs. Rhythm Control for Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 2004, 10, 45-53.	1.3	16
36	The State of Patient-Reported Outcomes in Atrial Fibrillation. Pharmacoeconomics, 2005, 23, 687-708.	3.3	19

#	ARTICLE	IF	CITATIONS
37	Implication from Randomized Trials of Rate and Rhythm Controls on Management of Patients with Persistent Atrial Fibrillation. <i>Annals of Noninvasive Electrocardiology</i> , 2006, 11, 170-186.	1.1	1
38	Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation J-RHYTHM Study. <i>Circulation Journal</i> , 2009, 73, 242-248.	1.6	198
39	Comparison of Antiarrhythmics Used in Patients With Paroxysmal Atrial Fibrillation. <i>Circulation Journal</i> , 2010, 74, 71-76.	1.6	11
40	Impact of Drug Alteration to Maintain Rhythm Control in Paroxysmal Atrial Fibrillation - Subanalysis From J-RHYTHM Study. <i>Circulation Journal</i> , 2010, 74, 870-875.	1.6	8
41	Impact of Lipid-Lowering Therapy on Outcomes in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2010, 105, 1768-1772.	1.6	10
42	Obesity and Outcomes Among Patients With Established Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2010, 106, 369-373.	1.6	54
43	Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm) Tj ETQq0 0 0 rgBT/Overlock, 10 Tf 50	2.8	113
44	An Observational, Prospective Survey Assessing the Control of Atrial Fibrillation in Asia Pacific: Rationale and Design of the RecordAF-AP Registry. <i>Clinical Medicine Insights: Cardiology</i> , 2011, 5, CMC.S6289.	1.8	3
45	The effects of radio-frequency ablation on blood pressure control in patients with atrial fibrillation and hypertension. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2012, 35, 285-291.	1.3	8
46	Effect of Warfarin on Outcomes in Septuagenarian Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2012, 109, 370-377.	1.6	16
47	The CHADS2 and CHA2DS2â€“VASc scores predict new occurrence of atrial fibrillation and ischemic stroke. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 37, 47-54.	1.3	47
48	Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. <i>European Heart Journal</i> , 2013, 34, 1489-1497.	2.2	175
49	Efficacy of Amiodarone in Patients with Atrial Fibrillation with and without Left Ventricular Dysfunction: A Pooled Analysis of AFFIRM and AFâ€“CHF Trials. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 1306-1313.	1.7	21
50	Risk of Ischemic Stroke in High Risk Atrial Fibrillation Patients during Periods of Warfarin Discontinuation for Surgical Procedures. <i>Cerebrovascular Diseases</i> , 2016, 42, 346-351.	1.7	4
51	Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 412-420.	3.3	78
52	Pharmacological cardioversion for atrial fibrillation and flutter. <i>The Cochrane Library</i> , 2017, 11, CD003713.	2.8	2
53	Paradigm shifts in pathophysiology and management of atrial fibrillationâ€“a tale of the RACE trials in the Netherlands. <i>Netherlands Heart Journal</i> , 2020, 28, 3-12.	0.8	5
54	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014932.	3.7	84

#	ARTICLE	IF	CITATIONS
55	The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis. PLoS ONE, 2017, 12, e0186856.	2.5	43
56	Atrial Fibrillation: The New Epidemic of the Ageing World. Journal of Atrial Fibrillation, 2009, 1, 154.	0.5	21
57	âĳfè†“ăfšăf14ă,ăf3ă,ăf»é»æ°—ç”Ÿç†ăĴç”ç©†ăéé2æ©(ă34ăç'oă™”ăĴ2000ă1”ăéé2æ©). Journal of JCS Cardiologists, 2000, 8, 339		
59	Present state of the development of antiarrhythmic agent and ideal way of clinical trial.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1998, 29, 837-841.	0.1	0
60	Atrial fibrillation: the most common arrhythmia. Texas Heart Institute Journal, 2000, 27, 257-67.	0.3	78
61	The return of "negative" trials?. Cmaj, 2003, 168, 1392-3; author reply 1393-4.	2.0	0
62	Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. Journal of Geriatric Cardiology, 2021, 18, 362-375.	0.2	1